期刊文献+

P-选择素在血栓形成中的作用及P-选择素抑制剂的研究进展 被引量:13

Role of P-selectin in thrombosis and research progress of P-selectin inhibitors
下载PDF
导出
摘要 血栓性疾病是人类的主要健康问题,缩短患者生存时间,影响患者生存质量。当心血管内膜损伤、血流或血液性质改变时会诱发血栓形成,按其形成部位可分为动脉血栓和静脉血栓。研究者们发现P-选择素在两种血栓的形成过程中都发挥着重要的作用,可以通过三条途径促进血栓形成。多年来科研工作者们设计了诸多类型的P-选择素抑制剂,根据机制可归纳为下调P-选择素表达类型和与P-选择素活性中心特异性结合类型,研究表明它们可以抑制血小板聚集、动脉血栓和静脉血栓形成,同时加速血栓的溶解。 Thrombosis is a major health problem in the world.It can shorten the survival time of patients and affect their life quality.Thrombosis can be induced when cardiovascular intimal injuries and blood flow or blood properties changes.Thrombosis can be divided into arterial thrombosis and venous thrombosis according to the site of formation.Researchers have found that P-selectin plays an important role in the formation of two types of thrombosis,and promotion of thrombosis in three ways.Over the years,researchers had designed many types of P-selectin inhibitors,according to the mechanism which could be divided into the down-regulation of P-selectin expression and the specific binding with P-selectin active center.These P-selectin inhibitors proved to inhibit platelet aggregation,arterial thrombosis and venous thrombosis,and accelerate thrombolysis at the same time.
作者 李泽 李新刚 沈素 LI Ze;LI Xin-gang;SHEN Su(Beijing Friendship Hospital Affiliated to Capital Medical University,Beijing 100050)
出处 《中南药学》 CAS 2020年第2期276-279,共4页 Central South Pharmacy
关键词 血栓性疾病 P-选择素 P-选择素抑制剂 抗血小板聚集 thrombotic disease P-selectin P-selectin inhibitor antiplatelet aggregation
  • 相关文献

参考文献2

二级参考文献28

  • 1袁莉娟,刘爱民,刘蕾.新型凝血酶抑制剂阿加曲班[J].中国新药杂志,2005,14(2):230-234. 被引量:34
  • 2Keam SJ,Goa KL.Fondaparinux sodium[J].Drugs,2002,62(11):1673.
  • 3Bauer KA,Hawkins DW,Peters PC,et al.Fondaparinux,a synthetic pentasaccharide:the first in a new class of antithrombotic agents-the selectivefactor Xa inhibitors[J].Cardiovasc Drug Rev,2002,20(1):37.
  • 4Charles W,FrancisM,Scott D,et al.Comparison of ximelagatran with warfain for the prevention of venous thromboembolism after total knee replacement[J].New Engl Med,2003,349(18):1703.
  • 5Boersma E,Akkerhuis KM,Theroux P,et al.Plateletglycoprorein glycoprotein Ⅱb/Ⅲa receptor inhibition in non-st-elevation acute coronary syndromes[J].Circulation,1999,100(20):2045.
  • 6Richard SG.Platelet aggregation inhibitors for use in peripheral vascular interventions:what can we lean from the experience in the coronary arteries[J].Vasc Interv Radiol,2002,13(3):229.
  • 7Rocha-Singh KJ,Trokey J.Combined glycoprotein Ⅱb/Ⅲa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis[J].Catheter Cardiovasc Interv,2002,55(4):457.
  • 8James E,David E,Cindy L,et al.Benefits and risks of abciximab use in primary angiopalasty for acute myocardial infarction[J].Circulation,2003,108(11):1316.
  • 9Dery JP,O'Shea JC,Tcheng JE.Eptifibatide in percutaneous coronary intervention[J].A review Minerva Cardioangiol,2002,50(5):531.
  • 10Ambrosini V,Battaglia S,Cioppa A,et al.Percutaneous femoral artery angioplasty with stent-in-stent technique and tirofiban administration[J].Invasive Cardiol,2002,14(10):619.

共引文献29

同被引文献157

引证文献13

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部